相关实验视频

Updated: Jun 26, 2025

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

帕金森氏症的特征在多重系统缩中的性质

Sunil Pradhan¹, Ruchika Tandon¹

¹Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.

Journal of neurosciences in rural practice

|May 15, 2024

概括

多重系统缩 (MSA) 中的帕金森特征有所不同,模仿帕金森病 (PD) 或渐进性超核性麻 (PSP). 早期的表现可能是欺骗性的,需要进行后续检查以准确诊断MSA.

科学领域:

神经学神经学
神经科学是一个神经科学.
临床医学临床医学

背景情况:

多重系统缩 (MSA) 呈现出不清楚的帕金森特征,使与帕金森病 (PD) 和渐进性超核性 (PSP) 的区别复杂化.
了解MSA中额外金字塔标志的频谱对于准确的诊断和患者管理至关重要.

研究的目的:

评估多重系统缩 (MSA) 患者帕金森特征的临床形状和变异性.
为了比较MSA中的额外金字塔呈现与通常在PD和PSP中看到的呈现.

主要方法:

一项观察性研究涉及57名被诊断患有MSA的患者,分为帕金森特征的MSA (MSA-P) 和带小脑特征的MSA (MSA-C).
在初次门诊或住院访问期间,对额外金字塔特征和勒沃多巴反应的临床评估.
对特征变异的分析和基于与PD或PSP相似性的分类.

主要成果:

在MSA的extrapyramidal特征是高度可变的,一些患者表现出PD-like标志 (例如,不对称性,震) 和其他PSP-like标志 (例如,对称性,轴刚性,跌倒).
很大一部分患者呈现混合呈现 (43.9%),而其他患者主要类似PD (36.8%) 或PSP (19.3%).
一个很高的百分比的患者 (86%) 显示了利沃多巴的反应,其中64%显示持续改善超过六个月.

结论:

在MSA中帕金森特征可以模仿PD或PSP,或呈现为混合图像.
在MSA中类似于PD或PSP的初始临床表现可能具有误导性,并且需要仔细跟进MSA的最终诊断.

关键词:

多重系统缩多重系统缩帕金森变异的多重系统缩.帕金森病是帕金森氏症的一种疾病.帕金森病类似的表现.渐进性的超核性.渐进的超核性麻类似的呈现.

更多相关视频

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

相关概念视频

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...